Protalix BioTherapeutics (PLX) Total Liabilities (2010 - 2026)

Protalix BioTherapeutics has reported Total Liabilities for 17 years, with the latest figure at $38.9 million in Q2 2026.

• On a quarterly basis, Total Liabilities rose 36.21% year-over-year to $38.9 million in Q2 2026; TTM through Jun 2026 was $38.9 million, a 36.21% increase from a year earlier, with the FY2025 full-year figure at $34.1 million, up 12.94% from the prior year.
• Total Liabilities was $38.9 million for Q2 2026 at Protalix BioTherapeutics, up from $35.1 million in the prior quarter.
• The five-year high for Total Liabilities was $75.9 million in Q1 2022, with the low at $28.6 million in Q2 2025.
• Average Total Liabilities over 5 years is $48.5 million, with a median of $49.4 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities plunged 54.6% in 2025, then surged 36.21% in 2026.
• Over 5 years, Total Liabilities stood at $66.4 million in 2022, then dropped by 23.43% to $50.9 million in 2023, then tumbled by 40.62% to $30.2 million in 2024, then climbed by 12.94% to $34.1 million in 2025, then gained by 14.12% to $38.9 million in 2026.
• The last three Total Liabilities figures came in at $38.9 million (Q2 2026), $35.1 million (Q1 2026), and $34.1 million (Q4 2025), per Business Quant data.